Polymerase Chain Reaction Market Insights, Future Trends, Growth estimation, Business Opportunities and Forecast By 2031
According to a recent report by Fact.MR, the demand for polymer chain reaction tests is expected to reach US$ 3.6 billion by the end of 2021 and is expected to reach US$ 12 billion by the end of the assessment period from 2021 to 2031. The polymerase chain reaction market (ポリメラエ連鎖电影市場) is threefold, with PCR reagents expected to account for 60% of total revenue.
In the field of medical diagnosis and biotechnology, polymerase chain reaction (PCR) technology has become an indispensable tool. Its importance has been further emphasized by recent advances in healthcare and the need for accurate and rapid testing, especially in the wake of the COVID-19 pandemic. Riding the wave of these healthy advances, the global polymerase chain reaction market has seen significant growth.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭
https://www.factmr.com/connectus/sample?flag=S&rep_id=4861
𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:
𝐓𝐡𝐞 𝐏𝐂𝐑 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧
The polymerase chain reaction, developed by Kary B. Mullis in 1983, revolutionized the way scientists study and diagnose genetic diseases. This technology allows DNA to be amplified, making it easier to detect even small amounts of genetic material. Over the years, PCR has become a cornerstone of molecular biology, genetic research, forensics and clinical diagnosis.
𝐊𝐞𝐲 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐨𝐟 𝐆𝐫𝐨𝐰𝐭𝐡
𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:
Leading industry players are adopting innovative strategies, including groundbreaking marketing approaches, technological advancements, and mergers and acquisitions, to expand their market presence.
In October 2021, Thermo Fisher Scientific, a US-based provider of scientific instrumentation, reagents, and consumables, introduced the Applied Biosystem QuantStudio Absolute Q-Digital PCR System. This marked the debut of a fully integrated digital PCR (dPCR) system designed to deliver highly accurate and consistent results in genetic analysis and research, all within a remarkable 90-minute timeframe.
In March 2021, Agilent Technologies Inc. announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. This kit has received the CE-IVD mark in compliance with the European Union In-Vitro Diagnostic Directive 98/79/EC and is readily available for distribution.
𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝
The global Polymerase Chain Reaction market has experienced impressive growth, driven by its essential role in healthcare advancements, particularly in the context of the COVID-19 pandemic. With ongoing technological innovations and expanding applications, PCR technology is set to remain at the forefront of molecular diagnostics and genetic research, offering hope for more effective disease diagnosis and management in the future.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.